Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Downgrades CME Group to Market Perform

Raymond James Downgrades CME Group to Market Perform

Raymond James analyst Patrick O'Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Raymond James analyst Patrick O’Shaughnessy downgrades CME Group (NASDAQ:CME) from Outperform to Market Perform.

Enveric Biosciences Receives Notice Of Allowance From USPTO For Novel Prodrug Of Psilocin

By Happy Mohamed

May 18, 8:09 AM

Intellectual property describes composition of matter claims governing Enveric's lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder Enveric Biosciences,

ENVB

Boeing Sees Solid June Deliveries, Boosting Confidence in Production Recovery – Analysts Optimistic

By Anusuya Lahiri

July 12, 1:34 PM

Susquehanna analyst Charles P.

RBC Capital Reiterates Sector Perform on Aramark, Maintains $48 Price Target

By Benzinga Newsdesk

February 8, 9:39 AM

RBC Capital analyst Ashish Sabadra reiterates Aramark (NYSE:ARMK) with a Sector Perform and maintains $48 price target.

ARMK

News

Turtle Beach Files For FCC ID Approval On ‘Stealth700X-MAX-RX 2790RX’

By Benzinga Newsdesk

July 22, 10:23 AM

https://fccid.io/XGB-2790RX

HEAR

Raymond James Downgrades CME Group to Market Perform

Related Posts

Enveric Biosciences Receives Notice Of Allowance From USPTO For Novel Prodrug Of Psilocin

Boeing Sees Solid June Deliveries, Boosting Confidence in Production Recovery – Analysts Optimistic

RBC Capital Reiterates Sector Perform on Aramark, Maintains $48 Price Target

Turtle Beach Files For FCC ID Approval On ‘Stealth700X-MAX-RX 2790RX’